85.59
price up icon1.22%   1.08
 
loading
Schlusskurs vom Vortag:
$84.51
Offen:
$85.44
24-Stunden-Volumen:
2.03M
Relative Volume:
0.48
Marktkapitalisierung:
$33.46B
Einnahmen:
$4.15B
Nettoeinkommen (Verlust:
$535.20M
KGV:
63.87
EPS:
1.34
Netto-Cashflow:
$575.20M
1W Leistung:
-2.30%
1M Leistung:
+19.08%
6M Leistung:
+9.26%
1J Leistung:
-33.01%
1-Tages-Spanne:
Value
$84.60
$85.70
1-Wochen-Bereich:
Value
$83.48
$87.00
52-Wochen-Spanne:
Value
$57.52
$128.63

Dexcom Inc Stock (DXCM) Company Profile

Name
Firmenname
Dexcom Inc
Name
Telefon
(858) 200-0200
Name
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Name
Mitarbeiter
10,300
Name
Twitter
@dexcom
Name
Nächster Verdiensttermin
2024-10-24
Name
Neueste SEC-Einreichungen
Name
DXCM's Discussions on Twitter

Vergleichen Sie DXCM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Medical Devices icon
DXCM
Dexcom Inc
85.33 34.25B 4.15B 535.20M 575.20M 1.34
Medical Devices icon
ABT
Abbott Laboratories
133.10 235.23B 42.34B 13.50B 6.66B 7.71
Medical Devices icon
BSX
Boston Scientific Corp
104.83 157.62B 17.55B 2.03B 2.72B 1.37
Medical Devices icon
SYK
Stryker Corp
382.50 148.87B 23.22B 2.86B 3.58B 7.40
Medical Devices icon
MDT
Medtronic Plc
81.18 110.72B 33.54B 4.66B 5.19B 3.62
Medical Devices icon
EW
Edwards Lifesciences Corp
76.22 45.66B 5.54B 4.18B 623.10M 7.00

Dexcom Inc Stock (DXCM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-10 Eingeleitet Mizuho Outperform
2025-02-03 Hochstufung Redburn Atlantic Neutral → Buy
2025-01-16 Hochstufung Robert W. Baird Neutral → Outperform
2024-07-26 Herabstufung JP Morgan Overweight → Neutral
2024-07-26 Herabstufung Robert W. Baird Outperform → Neutral
2024-05-30 Eingeleitet Redburn Atlantic Neutral
2024-03-12 Eingeleitet RBC Capital Mkts Outperform
2023-05-30 Fortgesetzt Morgan Stanley Equal-Weight
2023-04-17 Hochstufung Raymond James Outperform → Strong Buy
2023-03-29 Eingeleitet UBS Buy
2023-01-26 Eingeleitet Wolfe Research Outperform
2022-10-18 Eingeleitet Barclays Equal Weight
2022-10-12 Eingeleitet Jefferies Buy
2022-07-15 Eingeleitet Bernstein Outperform
2022-03-02 Fortgesetzt BofA Securities Buy
2022-02-03 Hochstufung BTIG Research Neutral → Buy
2022-01-19 Hochstufung Wells Fargo Equal Weight → Overweight
2022-01-07 Hochstufung Guggenheim Neutral → Buy
2021-10-18 Herabstufung Guggenheim Buy → Neutral
2021-07-21 Fortgesetzt Cowen Outperform
2021-05-28 Hochstufung Wells Fargo Underweight → Equal Weight
2021-05-25 Eingeleitet Barclays Overweight
2021-04-15 Eingeleitet Atlantic Equities Overweight
2021-01-06 Hochstufung UBS Neutral → Buy
2020-10-02 Herabstufung Wells Fargo Equal Weight → Underweight
2020-05-27 Bestätigt Piper Sandler Overweight
2020-05-14 Eingeleitet Wells Fargo Equal Weight
2020-03-05 Eingeleitet Citigroup Buy
2019-11-07 Bestätigt Canaccord Genuity Buy
2019-11-07 Hochstufung Guggenheim Neutral → Buy
2019-10-23 Eingeleitet Stifel Buy
2018-11-28 Eingeleitet UBS Neutral
2018-10-19 Hochstufung Goldman Sell → Neutral
2018-09-12 Hochstufung Northland Capital Under Perform → Market Perform
2018-08-02 Bestätigt Canaccord Genuity Buy
2018-07-02 Hochstufung Raymond James Mkt Perform → Outperform
2018-06-08 Hochstufung JP Morgan Neutral → Overweight
2018-05-11 Eingeleitet BofA/Merrill Buy
2018-05-03 Bestätigt Canaccord Genuity Buy
2018-04-04 Eingeleitet Goldman Sell
2018-04-04 Eingeleitet Guggenheim Neutral
2018-03-23 Hochstufung Robert W. Baird Neutral → Outperform
2018-01-04 Herabstufung Northland Capital Market Perform → Under Perform
2017-09-28 Bestätigt Wedbush Outperform
Alle ansehen

Dexcom Inc Aktie (DXCM) Neueste Nachrichten

pulisher
May 27, 2025

GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program - StreetInsider

May 27, 2025
pulisher
May 24, 2025

DexCom’s SWOT analysis: CGM leader faces supply challenges amid growth - Investing.com

May 24, 2025
pulisher
May 23, 2025

DexCom: Non-Insulin Type 2 Diabetes Market Penetration Be A Breakthrough Move? - Smartkarma

May 23, 2025
pulisher
May 23, 2025

An Intrinsic Calculation For DexCom, Inc. (NASDAQ:DXCM) Suggests It's 27% Undervalued - Yahoo Finance

May 23, 2025
pulisher
May 23, 2025

Blood Glucose Monitoring (BGM) Devices Market Report 2025: Hospitals Lead in Blood Glucose Monitoring Device Usage, Home Care Grows Fastest - GlobeNewswire Inc.

May 23, 2025
pulisher
May 22, 2025

DexCom (DXCM) Maintains Buy Rating as Price Target Raised to USD 102 | DXCM Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Citi Increases Price Target for DexCom (DXCM) to $102 | DXCM Stock News - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Diabetic Care Device Market Set for Significant Growth with 10.1% CAGR - GlobeNewswire Inc.

May 21, 2025
pulisher
May 21, 2025

Dexcom (DXCM) Gets a Buy from Wells Fargo - The Globe and Mail

May 21, 2025
pulisher
May 21, 2025

DexCom adds Renée Galá to Board of Directors By Investing.com - Investing.com Nigeria

May 21, 2025
pulisher
May 20, 2025

3 Big Reasons to Love DexCom (DXCM) - Yahoo Finance

May 20, 2025
pulisher
May 19, 2025

The End Of The Diabetes Industry?Eli Lilly (NYSE:LLY), DexCom (NASDAQ:DXCM) - Benzinga

May 19, 2025
pulisher
May 18, 2025

FDA Approves DexCom G4 Platinum Professional Continuous Glucose Monitoring System - Medical Product Outsourcing

May 18, 2025
pulisher
May 17, 2025

Can DexCom, Inc. (NASDAQ:DXCM) Maintain Its Strong Returns? - Yahoo Finance

May 17, 2025
pulisher
May 16, 2025

Here's Why You Should Add DexCom Stock to Your Portfolio Now - MSN

May 16, 2025
pulisher
May 16, 2025

Dexcom CEO says CGMs fit MAHA agenda ‘very nicely’; Tandem preps for new products - MedTech Dive

May 16, 2025
pulisher
May 16, 2025

Is DexCom, Inc. (NASDAQ:DXCM) Trading At A 24% Discount? - simplywall.st

May 16, 2025
pulisher
May 16, 2025

Do Wall Street Analysts Like DexCom Stock? - Nasdaq

May 16, 2025
pulisher
May 15, 2025

DXCM Q1 Earnings Call: Coverage Expansion and Product Pipeline Shape 2025 Outlook - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Dexcom Beats Investor Claims Over Sales Growth Potential for Now - Bloomberg Law News

May 15, 2025
pulisher
May 15, 2025

5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil - TradingView

May 15, 2025
pulisher
May 15, 2025

Dexcom Beats Investor Claims Over Growth Potential for Now (1) - Bloomberg Law News

May 15, 2025
pulisher
May 14, 2025

DexCom, Inc. (DXCM) Announces Leadership Promotion: Jacob S. Lea - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO | DXCM Stock News - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO - GuruFocus

May 13, 2025
pulisher
May 13, 2025

DexCom (DXCM) Elevates Jake Leach to President - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Dexcom promotes Jake Leach to president role - MassDevice

May 13, 2025
pulisher
May 13, 2025

The Zacks Analyst Blog Highlights Sprouts Farmers Market, DexCom, Hims & Hers Health, United Natural Foods and GoodRx - TradingView

May 13, 2025
pulisher
May 13, 2025

Dexcom Promotes Jake Leach to Expanded President, COO Role - Medical Product Outsourcing

May 13, 2025
pulisher
May 13, 2025

DexCom Adds President Role to COO Jake Leach - marketscreener.com

May 13, 2025
pulisher
May 12, 2025

All You Need to Know About DexCom (DXCM) Rating Upgrade to Buy - Yahoo Finance

May 12, 2025
pulisher
May 12, 2025

Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns - TradingView

May 12, 2025
pulisher
May 12, 2025

DexCom Stock: Earnings Beat and New Market Access Drive Bull Case - MSN

May 12, 2025
pulisher
May 11, 2025

DXCM STOCK NOTICE: Did DexCom, Inc. Commit Securities Fraud? Investors are Urged to Contact BFA Law about its Investigation if You Suffered Losses (DXCM) - ACCESS Newswire

May 11, 2025
pulisher
May 09, 2025

Investor Network: DexCom, Inc. to Host Earnings Call - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

DexCom, Inc. (DXCM) Announces Key Approvals at Annual Meeting - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Shareholders of DexCom, Inc. Should Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your RightsDXCM - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

Dexcom Stockholders Approve Equity Plan Amendments - TipRanks

May 09, 2025
pulisher
May 09, 2025

DXCM STOCK NOTICE: DexCom, Inc. Investors that Suffered Losses are Notified a Securities Fraud Investigation has been Initiated against DXCM and are Urged to Contact BFA Law - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure (NASDAQ:DXCM) - Seeking Alpha

May 09, 2025
pulisher
May 09, 2025

Should You Investigate DexCom, Inc. (NASDAQ:DXCM) At US$85.34? - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Is DexCom, Inc. (DXCM) the Best Medical Device Stock to Buy Now? - Insider Monkey

May 09, 2025
pulisher
May 09, 2025

Shareholders that lost money on DexCom, Inc.(DXCM) should contact Levi & Korsinsky about pending Class ActionDXCM - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

Class Action Filed Against DexCom, Inc. (DXCM) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

Lost Money on DexCom, Inc. (DXCM)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

Shareholders that lost money on DexCom, Inc.(DXCM) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

DexCom, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before October 21, 2024 to Discuss Your RightsDXCM - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

Levi & Korsinsky Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – DXCM - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

Levi & Korsinsky Notifies Shareholders of DexCom, Inc.(DXCM) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

May 09, 2025

Finanzdaten der Dexcom Inc-Aktie (DXCM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$71.01
price up icon 2.67%
medical_devices SNN
$28.92
price up icon 1.01%
medical_devices STE
$246.20
price up icon 1.32%
$326.64
price up icon 1.64%
medical_devices EW
$76.22
price up icon 1.64%
Kapitalisierung:     |  Volumen (24h):